131994-35-9

Upstream product

• 106-49-0 p-toluidine 
• 131994-01-9 (Z)-3-Dimethylamino-2-(2-fluoro-4-pyridin-4-yl-benzoyl)-acrylic acid ethyl ester 
• 110-86-1 pyridine 
• 452-75-5 4-chloro-2-fluorotoluene 
• 131993-99-2 2-fluoro-4-(4-pyridinyl)benzoic acid 
• 131994-00-8 ethyl 2-fluoro-4-(4-pyridinyl)-β-oxobenzenepropanoate 
• 148648-27-5 2-fluoro-4-(pyridine-4-yl)benzoyl chloride 
• 148627-75-2 4-(3-fluoro-4-methylphenyl)pyridine 

Relevant academic research and scientific papers

3-Quinolinecarboxamides. A series of novel orally-active antiherpetic agents

A series of novel 3-quinolinecarboxamides that are structurally similar to the quinolone class of antibacterial agents possess excellent antiherpetic properties. By modifying the quinoline ring at the 1-, 2-, 3-, and 7- positions, analogues were identified that have up to 5-fold increased HSV-2 plaque-reduction potency relative to acyclovir. In a single-dose mouse model of infection, one of the most potent derivatives in vitro, 1-(4- fluorophenyl)-1,4-dihydro-4-oxo-7-(4-pyridinyl)-3-quinolinecarboxamide (97), displayed comparable oral antiherpetic efficacy to acyclovir at 1/16 the dose; in a multiple-dose regimen, however, 97 was 2-fold less potent. In mice dosed orally with 97, sustained plasma drug levels were evident that may account for the high efficacy observed. The molecular mechanism of action of these agents is not known; however, based on in vitro studies with acyclovir resistant mutants, it is likely that the mechanism differs from that of acyclovir. In vitro plaque-reduction potency was not generally predictive of oral efficacy in mice. An X-ray crystal structure of 97 corroborated the assignment of structure and provided useful insights as to the effect of conformation on plaque-reduction potency.

Quinolonecarboxamide compounds, their preparation and use as antivirals.

Compounds of the formula STR1 where R is hydrogen, hydroxy, amino or lwer-alkyl; R1 is lower-alkyl, lower-alkenyl, cycloalkyl, pyridinyl, phenyl or substituted phenyl; R2 is hydrogen, amino or hydroxy; R6 is hydrogen or fluoro; and R7 is phenyl, pyridinyl or selected other heterocycles, have antiviral acitivity against herpes virus. The compounds are prepared from the corresponding carboxylic acids or ester, or by a tin-coupling reaction on the corresponding 7-halo compounds.